Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on recently approved and emerging therapeutic strategies in the management of breast cancer. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.
If you are interested in hosting a session at your institution, please email our Meeting Services Department at GRTeam@ResearchToPractice.com or call (800) 233-6153.
Schedule of Events
Events to be announced
There is no registration fee for these events. However, preregistration is advised as seating is limited.
Each 1-hour session will include 5 topic modules focused on the current management of breast cancer and research information on novel strategies under active investigation. Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Polling Results
MODULE 1 Chemotherapy with Immunotherapy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
MODULE 2 T-DM1 for Residual HER2-Positive Disease After Neoadjuvant Therapy
MODULE 3 PARP Inhibitors in Metastatic Breast Cancer
MODULE 4 PI3 Kinase Inhibitors in Hormone Receptor-Positive Metastatic Disease
MODULE 5 Novel HER2-Directed Investigational Approaches
Each session will conclude with a 5-minute Q&A segment
STEERING COMMITTEE MEMBERS
Harold J Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Charles E Geyer Jr, MD
Professor of Medicine
Virginia Commonwealth University School
of Medicine
Harrigan, Haw, Luck Families Chair in
Cancer Research
Associate Director of Clinical Research
Massey Cancer Center
Richmond, Virginia
Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Sara A Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Santa Monica, California
Rita Nanda, MD
Co-Director, Breast Medical Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast
Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Sara M Tolaney, MD, MPH
Associate Director, Susan F Smith Center for Women’s Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Project Chair
Neil Love, MD
President
Research To Practice
Miami, Florida
Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.
Learning Objectives
- Appraise recently presented Phase III data supporting the FDA approval of an antibody-drug conjugate as adjuvant therapy for patients with HER2-overexpressing early breast cancer who have residual invasive disease after neoadjuvant therapy with trastuzumab and taxane-based chemotherapy, and use this information to appropriately integrate this approach into routine practice.
- Review published efficacy and safety data with the use of approved PARP inhibitors for patients with metastatic breast cancer harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings for nonresearch care.
- Recall the biologic rationale for and design of ongoing clinical trials evaluating other investigational PARP inhibitors or novel PARP inhibitor combinations (eg, with immunotherapy or chemotherapy) for breast cancer, and counsel appropriate patients about availability and participation.
- Appraise recently presented Phase III data supporting the FDA approval of anti-PD-L1 antibody therapy combined with chemotherapy for newly diagnosed PD-L1-positive metastatic triple-negative breast cancer, and use this information to identify patients who may be appropriate for this approach in clinical practice.
- Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for breast cancer, and counsel appropriate patients about availability and participation.
- Recognize the frequency of PI3K (phosphoinositide-3 kinase) pathway mutations in patients with ER-positive metastatic breast cancer, and consider published research data documenting the efficacy and safety of newly approved and novel agents targeting these abnormalities.
- Assess ongoing clinical research evaluating novel agents and treatment strategies for metastatic HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.
CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.
Commercial Support
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Merck, Novartis and Seattle Genetics.
|
